1. Home
  2. FUTU vs INCY Comparison

FUTU vs INCY Comparison

Compare FUTU & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Futu Holdings Limited

FUTU

Futu Holdings Limited

N/A

Current Price

$113.43

Market Cap

17.1B

Sector

Finance

ML Signal

N/A

Logo Incyte Corp.

INCY

Incyte Corp.

N/A

Current Price

$113.15

Market Cap

17.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FUTU
INCY
Founded
2011
1991
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Commercial Physical & Biological Resarch
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.1B
17.0B
IPO Year
2018
1994

Fundamental Metrics

Financial Performance
Metric
FUTU
INCY
Price
$113.43
$113.15
Analyst Decision
Strong Buy
Buy
Analyst Count
18
28
Target Price
★ $160.84
$129.13
AVG Volume (30 Days)
788.9K
★ 1.5M
Earning Date
11-17-2026
10-29-2026
Dividend Yield
★ 2.39%
N/A
EPS Growth
N/A
★ 4173.33
EPS
N/A
★ 1.47
Revenue
N/A
★ $3,394,635,000.00
Revenue This Year
$20.19
$15.49
Revenue Next Year
$3.97
$5.35
P/E Ratio
★ $17.05
$76.70
Revenue Growth
N/A
★ 13.67
52 Week Low
$80.50
$82.82
52 Week High
$202.53
$132.60

Technical Indicators

Market Signals
Indicator
FUTU
INCY
Relative Strength Index (RSI) 52.77 32.66
Support Level $108.21 $110.56
Resistance Level $117.04 $119.29
Average True Range (ATR) 3.84 3.20
MACD 0.11 -1.20
Stochastic Oscillator 76.21 16.85

Price Performance

Historical Comparison
FUTU
INCY

About FUTU Futu Holdings Limited

Futu Holdings Ltd is an online broker providing one-stop online investing services.. Through its proprietary digital platforms, Futubull and Moomoo, the Company provides a full range of investment services, including trade execution and clearing, margin financing and securities lending, and wealth management. The Group engages in online brokerage services and margin financing services. It generates its revenue in the form of brokerage commission and handling charge services, and interest income. Geographically, it operates in Hong Kong, which derives key revenue and it also has its presence in other countries.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: